About
About Hisamitsu Pharmaceutical Co., Inc
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.
Visit company website
5 years, 6 months ago
Hisamitsu Pharmaceutical Co., Inc is currently in a long term downtrend where the price is trading 15.4% below its 200 day moving average.
From a valuation standpoint, the stock is 93.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.9.
Hisamitsu Pharmaceutical Co., Inc's total revenue sank by 21.8% to $28B since the same quarter in the previous year.
Its net income has dropped by 74.2% to $2B since the same quarter in the previous year.
Based on the above factors, Hisamitsu Pharmaceutical Co., Inc gets an overall score of 1/5.